Geisinger and Eisai to test real-world validity of AI-powered Passive Digital Marker (PDM) in detecting early cognitive impairment and dementia

Research collaboration will test novel algorithm’s effectiveness on Geisinger data (press release): Geisinger and Eisai Inc. today announced a collaborative effort to study the potential effectiveness of an artificial intelligence (AI) tool in the detection of cognitive impairment that could identify dementias, including Alzheimer’s disease (AD). If effective, the AI tool could potentially be developed to support the early detection and staging of cognitive impairment and dementia, leading to appropriate additional testing for the clinical, biological diagnosis and treatment of dementias such as AD. The research collaboration will study the use of an algorithm trained on a set of de-identified patient data to identify individuals likely to have cognitive impairment. The algorithm, known as a Passive Digital Marker (PDM), was developed and tested by researchers at Purdue University and Indiana University … “AI technology has the potential to transform medicine,” said Yasser El-Manzalawy, Ph.D., principal investigator and assistant professor of Translational Data Science and Informatics at Geisinger. “AI-based tools can efficiently scan massive amounts of healthcare data and identify hidden patterns. These patterns can be used to detect diseases, like cancer and dementia, at an early stage…” “As an implementation scientist, it is always exciting to have other scientists evaluate the reproducibility of the performance of our passive digital marker in very diffe...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Brain/ Mental Health Technology & Innovation algorithm Alzheimer’s Disease artificial intelligence Cognitive-impairment dementia Eisai electronic medical records Geisinger machine-learning Passive Digital Marker Source Type: blogs